The $8-per-share deal will give Sanofi control of Vigil's VG-3927, an oral drug candidate for Alzheimer's that acts as an ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

In summary, although deal volume is down, there are fewer but larger deal sizes. Life sciences companies that can demonstrate ...

Meanwhile at SpinCo, a new spinoff of Galapagos, Henry Gosebruch was appointed CEO. Gosebruch was previously president and ...

NICE is also looking at the role of Hympavzi in treating severe haemophilia A, where there are other subcutaneous options ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and ...

Shares in the digital therapeutics (DTx) developer closed up more than 17% after its debut on the NYSE at $32 under the HNGE ...

According to the CDC, cases of myocarditis and pericarditis are rare with the vaccines and, in most cases, resolve within a ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...